Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy
Austedo And Uzedy Key To Near-Term Growth
New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.
You may also be interested in...
The company also announced plans to divest its active pharmaceutical ingredients (API) business as part of its ‘Pivot to Growth’ strategy.
As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.
Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.